Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MZF1 possesses a repressively regulatory function in ERCC1 expression.

Qing-Wu Yan1, Eddie Reed, Xiao-Song Zhong

  • 1Department of Biochemistry and Molecular Pharmacology, and Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, 1610-C Health Sciences South, Morgantown, WV 26506-9300, USA.

Biochemical Pharmacology
|January 24, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The future of sleep apnea management: we can either ride the bus or drive it.

Frontiers in sleep·2025
Same author

Dicycloplatin, a Novel Analog of Cisplatin and Carboplatin, May Provide Therapeutic Advancement in Cancer Chemotherapy.

Anticancer research·2025
Same author

Rapid cycling and emission of volatile sulfur compounds in the eastern Indian Ocean: Impact of runoff inputs and implications for balancing atmospheric carbonyl sulfide budget.

Water research·2024
Same author

Revealing the Marine Cycles of Volatile Sulfur Compounds and Their Biogeochemical Controls: A Case of the Western North Pacific.

Environmental science & technology·2024
Same author

[Optimization of β-globin Stable Expression Using the Third Generation Lentiviral Vector for β-thalassemia Therapy].

Zhongguo shi yan xue ye xue za zhi·2022
Same author

First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report.

Anticancer research·2022

This study identifies key DNA regions regulating ERCC1 gene expression, crucial for platinum-chemotherapy resistance in ovarian cancer. Cisplatin treatment alters transcription factors MZF1 and AP1, impacting ERCC1 levels and offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Drug Resistance Mechanisms

Background:

  • ERCC1 is vital for DNA repair and platinum-chemotherapy resistance.
  • ERCC1 overexpression is linked to cisplatin resistance in ovarian cancer.
  • Transcriptional regulation of ERCC1 involves various factors in its 5'-flanking region.

Purpose of the Study:

  • To identify the minimal promoter region essential for ERCC1 transcription.
  • To investigate the regulatory elements responsible for cisplatin-induced ERCC1 expression.
  • To elucidate the roles of transcription factors MZF1 and AP1 in ERCC1 regulation.

Main Methods:

  • CAT assay to define the core promoter region.
  • Electrophoretic mobility shift assay (EMSA) to study transcription factor binding.

Related Experiment Videos

  • Quantitative PCR to analyze MZF1 mRNA levels.
  • Co-transfection assays to assess MZF1's regulatory function.

    • Main Results:

    • A core promoter region (-220 to -110) is essential for constitutive ERCC1 expression.
    • A distinct upstream region mediates cisplatin-induced ERCC1 expression.
    • Cisplatin treatment alters binding activity at MZF1-like and AP1-like sites.
    • MZF1 acts as a repressor, while AP1 acts as an activator of ERCC1 transcription.

    Conclusions:

    • ERCC1 expression is tightly regulated by its promoter, with distinct regions for basal and drug-induced transcription.
    • MZF1 and AP1 are key regulators of ERCC1 in response to cisplatin.
    • Understanding these regulatory mechanisms offers potential strategies to overcome platinum-chemotherapy resistance in ovarian cancer.